Tempus AI Expands Oncology Data Partnership With Bristol Myers Squibb Through 2031
Bitget2026/10/23 13:02- Tempus AI expanded its collaboration with Bristol Myers Squibb under a multiyear oncology data licensing agreement running through 2031.
- The agreement makes Bristol Myers Squibb one of its largest licensees of de-identified oncology data, supporting drug discovery and therapeutic development.
- Bristol Myers Squibb will also access the Lens Platform to train and run AI models using de-identified data and dedicated GPU infrastructure.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US stock contracts related to AI cloud computing infrastructure collectively fell over the past 24 hours
Northland: The transaction between Mawell Technology and Lumentum highlights the scarce value of InP devices, benefiting related U.S. concept stocks
Northland Capital Markets has upgraded the ratings of Coherent and Applied Optoelectronics following MaxLinear's acquisition of Lumentum.

Goldman Sachs: Maintains "Buy" rating for EQT Energy (EQT.US); Mountain Resources acquisition has strategic significance
Goldman Sachs maintains a "Buy" rating on EQT Energy with a target price of $62.